Literature DB >> 18339592

13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.

L Dinesen1, W F Caspary, R W Chapman, C F Dietrich, C Sarrazin, B Braden.   

Abstract

BACKGROUND: The (13)C-methacetin-breath test and also several noninvasive blood tests comprising routine laboratory parameters have been proposed to predict fibrosis and cirrhosis in chronic hepatitis C. The aim of the study was to compare the diagnostic accuracy between these tests referring to hepatic histology as gold standard.
METHODS: 96 patients with chronic hepatitis C virus infection underwent percutaneous liver biopsy and the (13)C-methacetin-breath test. The Fibroindex, the aspartate aminotransferase to platelet ratio index , and the aspartate aminotransferase to alanine aminotransferase ratio were used as parameters for the staging of fibrosis. The main endpoint was the area under the characteristic curves for the diagnosis of advanced fibrosis (F3-F4) and cirrhosis (F4) according to the Batts Ludwig criteria.
RESULTS: ROC analysis revealed a cut-off <14.6 per thousand best with 92.6% sensitivity and 84.1% specificity for the (13)C-methacetin-breath test, for the Fibroindex >1.82 70.4% sensitivity and 91.3% specificity, for the aspartate aminotransferase to platelet ratio >1.0 a 66.7% sensitivity and 75.4% specificity, and for the aspartate aminotransferase to alanine aminotransferase ratio >1.0 63.0% sensitivity and 59.4% specificity in predicting liver cirrhosis. The areas under the curve for the breath test, the Fibroindex, aspartate aminotransferase to platelet ratio and the aspartate aminotransferase to alanine aminotransferase ratio were 0.958, 0.845, 0.799, and 0.688, respectively, when predicting cirrhosis. For identifying patients with advanced fibrosis, the areas under the curve were 0.827, 0.804, 0.779, and 0.561, respectively. Discordances between Fibroindex (21%), aspartate aminotransferase to platelet ratio (29%) or aspartate aminotransferase to alanine aminotransferase ratio (37.6%) and liver biopsy were significantly more frequent than between (13)C-breath test (11.6%) and liver biopsy (P<0.05).
CONCLUSION: The (13)C-methacetin-breath test is more reliable in predicting advanced fibrosis and cirrhosis than simple biochemical parameters (aspartate aminotransferase to platelet ratio; aspartate aminotransferase to alanine aminotransferase ratio).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339592     DOI: 10.1016/j.dld.2008.01.013

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  A novel variant of the 13C-methacetin liver function breath test that eliminates the confounding effect of individual differences in systemic CO2 kinetics.

Authors:  Hermann-Georg Holzhütter; Tilo Wuensch; Robert Gajowski; Nikolaus Berndt; Sascha Bulik; David Meierhofer; Martin Stockmann
Journal:  Arch Toxicol       Date:  2020-02-04       Impact factor: 5.153

2.  Diagnostic value of the C methacetin breath test in various stages of chronic liver disease.

Authors:  Hamizah Razlan; Nurhayaty Muhamad Marzuki; Mei-Ling Sharon Tai; Azhar-Shah Shamsul; Tze-Zen Ong; Sanjiv Mahadeva
Journal:  Gastroenterol Res Pract       Date:  2011-06-07       Impact factor: 2.260

Review 3.  (13)CO2 breath tests in non-invasive hepatological diagnosis.

Authors:  Joanna Musialik; Krzysztof Jonderko; Anna Kasicka-Jonderko; Magdalena Buschhaus
Journal:  Prz Gastroenterol       Date:  2015-01-14

Review 4.  Dynamic carbon 13 breath tests for the study of liver function and gastric emptying.

Authors:  Leonilde Bonfrate; Ignazio Grattagliano; Giuseppe Palasciano; Piero Portincasa
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-21

Review 5.  13C Methacetin Breath Test for Assessment of Microsomal Liver Function: Methodology and Clinical Application.

Authors:  Katarzyna Gorowska-Kowolik; Agata Chobot; Jaroslaw Kwiecien
Journal:  Gastroenterol Res Pract       Date:  2017-07-05       Impact factor: 2.260

6.  (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle.

Authors:  Emilio Molina-Molina; Harshitha Shanmugam; Agostino Di Ciaula; Ignazio Grattagliano; Domenica Maria Di Palo; Vincenzo O Palmieri; Piero Portincasa
Journal:  JHEP Rep       Date:  2020-11-04

Review 7.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.